Welcome to our dedicated page for Check Cap news (Ticker: CHEK), a resource for investors and traders seeking the latest updates and insights on Check Cap stock.
News and filings around Check-Cap Ltd. (NASDAQ: CHEK) trace the company’s evolution from a clinical stage medical diagnostics developer into a business centered on embodied artificial intelligence through its merger with MBody AI. Historically, Check-Cap announcements focused on its C-Scan® investigational device, an ingestible imaging capsule designed for preparation-free colorectal cancer screening, along with regulatory milestones and shareholder communications about its intellectual property and strategic alternatives.
More recent news is dominated by the definitive Agreement and Plan of Merger with MBody AI, a Nevada corporation described as a market leader in embodied artificial intelligence. Press releases and Form 6-K reports highlight shareholder approval of the merger, plans to rename the combined company “MBody AI Ltd.”, and the strategic rationale of combining Check-Cap’s legacy assets with MBody AI’s AI orchestration platform. Coverage includes details of the MBody AI Orchestrator™ platform, its hardware-agnostic architecture, and its deployment across Fortune 500 enterprises and blue-chip brands.
Investors following CHEK news can expect updates on merger progress, shareholder meeting outcomes, Nasdaq listing and compliance matters, and any financing or capital markets activity tied to the combined company’s growth strategy. Additional items include legal and governance-related press releases, as well as communications about Check-Cap’s acquisition of exclusive Ghost Kitchen franchise rights in New Jersey. This news feed offers a consolidated view of corporate developments, strategic transactions, and regulatory disclosures that shape the investment narrative for CHEK.
For those tracking the transition from medical diagnostics to embodied AI and related automation themes, the CHEK news page provides ongoing context on how Check-Cap and MBody AI present their business model, market positioning and long-term plans through official announcements and SEC-furnished materials.
Check-Cap (NASDAQ: CHEK) announced FDA approval for its Investigational Device Exemption (IDE), allowing the initiation of a pivotal study for its revolutionary C-Scan® colorectal cancer screening test. This patient-friendly, preparation-free method targets individuals at average risk who are poor candidates for traditional colonoscopy. The study aims to assess C-Scan's safety and performance, with plans to enroll 250 patients across clinical sites in Israel. The FDA also granted Breakthrough Device Designation for C-Scan, emphasizing its potential in addressing unmet needs for CRC screening.
Check-Cap Ltd. (NASDAQ: CHEK) updated shareholders on its progress with the C-Scan technology, a unique screening test for colorectal cancer. In 2020, the company finalized its pivotal study design and submitted an IDE to the FDA. Manufacturing is underway, supported by a $750,000 grant from the Israel Innovation Authority. The company regained NASDAQ compliance as of January 26, 2021, and raised funds totaling approximately $34.8 million for its U.S. initiatives. The C-Scan aims to enhance screening adherence, with ongoing studies and patent protections bolstering its market presence.
Check-Cap Ltd. (NASDAQ: CHEK) submitted an Investigational Device Exemption application to the FDA for its C-Scan® pivotal study on November 18, 2020. The IDE submission marks a significant milestone as the company aims to advance its non-invasive colorectal cancer screening solution. Financially, Check-Cap reported a net loss of approximately $3.6 million in Q3 2020, similar to Q3 2019, with cash reserves of approximately $21.7 million. Research and development expenses remained stable, totaling $2.7 million. The company anticipates providing updates on study timelines in 2021.
Check-Cap Ltd. (NASDAQ: CHEK) reported financial results for Q2 2020, showing a net loss of $2.9 million, down from $3.4 million in Q2 2019. The company raised $16.3 million through offerings and has a cash position of $16.4 million as of June 30, 2020. With the Investigational Device Exemption submission to the FDA planned for late 2020 and a U.S. pivotal study beginning in 2021, Check-Cap aims to advance its C-Scan® colon cancer screening technology. Despite challenges posed by COVID-19, operations have resumed, aided by successful fundraising efforts.
Check-Cap Ltd. (NASDAQ: CHEK) announced a definitive agreement with institutional investors to exercise outstanding warrants for 16,054,223 ordinary shares at $0.60 per share, generating approximately $9.6 million in gross proceeds. The warrants, issued from November 2017 to May 2020, had previously higher exercise prices. The funds will be used to advance the clinical development of their C-Scan®, a non-invasive colorectal cancer screening test, and for general corporate purposes. Closing is expected around July 27, 2020, subject to customary conditions.